149 related articles for article (PubMed ID: 30896061)
1. Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation status.
Means C; Clayburgh DR; Maloney L; Sauer D; Taylor MH; Shindo ML; Coussens LM; Tsujikawa T
Head Neck; 2019 Aug; 41(8):2636-2646. PubMed ID: 30896061
[TBL] [Abstract][Full Text] [Related]
2. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
[TBL] [Abstract][Full Text] [Related]
3. BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma.
Givens DJ; Buchmann LO; Agarwal AM; Grimmer JF; Hunt JP
Laryngoscope; 2014 Sep; 124(9):E389-93. PubMed ID: 24604709
[TBL] [Abstract][Full Text] [Related]
4. Papillary thyroid carcinoma behavior: clues in the tumor microenvironment.
Bergdorf K; Ferguson DC; Mehrad M; Ely K; Stricker T; Weiss VL
Endocr Relat Cancer; 2019 Jun; 26(6):601-614. PubMed ID: 30965283
[TBL] [Abstract][Full Text] [Related]
5. Imbalance in DNA repair machinery is associated with BRAF
Lutz BS; Leguisamo NM; Cabral NK; Gloria HC; Reiter KC; Agnes G; Zanella V; Meyer ELS; Saffi J
Mol Cell Endocrinol; 2018 Sep; 472():140-148. PubMed ID: 29229408
[TBL] [Abstract][Full Text] [Related]
6. BRAF
Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
[TBL] [Abstract][Full Text] [Related]
7. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
[TBL] [Abstract][Full Text] [Related]
8. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
[TBL] [Abstract][Full Text] [Related]
9. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
[TBL] [Abstract][Full Text] [Related]
10. Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.
Guo M; Chen Z; Li Y; Li S; Shen F; Gan X; Feng J; Cai W; Liu Q; Xu B
Front Endocrinol (Lausanne); 2021; 12():674616. PubMed ID: 34248843
[TBL] [Abstract][Full Text] [Related]
11. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A
Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105
[TBL] [Abstract][Full Text] [Related]
12. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS
Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810
[TBL] [Abstract][Full Text] [Related]
14. Coexistence of
Rusinek D; Pfeifer A; Krajewska J; Oczko-Wojciechowska M; Handkiewicz-Junak D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Cyplinska R; Zembala-Nozynska E; Chekan M; Chmielik E; Kropinska A; Lamch R; Jurecka-Lubieniecka B; Jarzab B; Czarniecka A
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30200646
[No Abstract] [Full Text] [Related]
15. Inhibition of BRAF Sensitizes Thyroid Carcinoma to Immunotherapy by Enhancing tsMHCII-mediated Immune Recognition.
Zhi J; Zhang P; Zhang W; Ruan X; Tian M; Guo S; Zhang W; Zheng X; Zhao L; Gao M
J Clin Endocrinol Metab; 2021 Jan; 106(1):91-107. PubMed ID: 32936899
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma.
Sun J; Zhang J; Lu J; Gao J; Lu T; Ren X; Duan H; Liang Z
Int J Clin Exp Pathol; 2015; 8(11):15072-8. PubMed ID: 26823846
[TBL] [Abstract][Full Text] [Related]
17. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
[TBL] [Abstract][Full Text] [Related]
18. Combined effect of Hashimoto's thyroiditis and BRAF(V600E) mutation status on aggressiveness in papillary thyroid cancer.
Kim SJ; Myong JP; Jee HG; Chai YJ; Choi JY; Min HS; Lee KE; Youn YK
Head Neck; 2016 Jan; 38(1):95-101. PubMed ID: 25213729
[TBL] [Abstract][Full Text] [Related]
19. STRA6 regulates tumor immune microenvironment and is a prognostic marker in BRAF-mutant papillary thyroid carcinoma.
He W; Sun Y; Ge J; Wang X; Lin B; Yu S; Li Y; Hong S; Xiao H
Front Endocrinol (Lausanne); 2023; 14():1076640. PubMed ID: 36843593
[TBL] [Abstract][Full Text] [Related]
20. BRAFV600E and BRAF-WT Specific Antitumor Immunity in Papillary Thyroid Cancer.
Ehlers M; Schmidt M; Mattes-Gyorgy K; Antke C; Enczmann J; Schlensog M; Japp A; Haase M; Allelein S; Dringenberg T; Giesel F; Esposito I; Schott M
Horm Metab Res; 2022 Dec; 54(12):852-858. PubMed ID: 36427494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]